FDA Asks Pfizer to Test Second Paxlovid Course in Patients With COVID Rebound
The U.S. Food and Drug Administration (FDA) has asked Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.
Reuters Health Information
source https://www.medscape.com/viewarticle/979509?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/979509?src=rss
Comments
Post a Comment